Genix Pharmaceuticals Corp (GENX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 10/31
| 04-2024 | 01-2024 | 10-2023 | 07-2023 | 04-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 10 | 9 | 12 | 4 | 40 |
| Receivables | 4 | 3 | 1 | 13 | 15 |
| Inventories | 160 | 161 | 159 | 162 | 163 |
| TOTAL | $240 | $239 | $216 | $242 | $288 |
| Non-Current Assets | |||||
| Intangibles | 7 | 8 | 8 | 3,601 | 3,737 |
| TOTAL | $7 | $8 | $8 | $3,601 | $3,737 |
| Total Assets | $247 | $247 | $223 | $3,842 | $4,025 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 661 | 575 | 512 | 421 | 394 |
| Accounts payable and accrued liabilities | 281 | 281 | 249 | 265 | 283 |
| Accrued Expenses | 10 | 15 | 20 | 15 | 34 |
| Other current liabilities | 578 | 572 | 580 | 568 | 575 |
| TOTAL | $1,530 | $1,443 | $1,361 | $1,269 | $1,287 |
| Non-Current Liabilities | |||||
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,530 | $1,443 | $1,361 | $1,269 | $1,287 |
| Shareholders' Equity | |||||
| Common Shares | 9,701 | 9,701 | 9,701 | 9,701 | 9,701 |
| Retained earnings | -12,276 | -12,190 | -12,131 | -8,360 | -8,196 |
| Other shareholders' equity | 1,293 | 1,293 | 1,293 | 1,233 | 1,233 |
| TOTAL | $-1,282 | $-1,196 | $-1,137 | $2,574 | $2,738 |
| Total Liabilities And Equity | $247 | $247 | $223 | $3,842 | $4,025 |